{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genes%2C+BRCA+1", "query": { "condition": "Genes, BRCA 1" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genes%2C+BRCA+1&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T04:09:53.285Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02598895", "title": "Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration Levels of Testosterone", "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Prostate Carcinoma Metastatic in the Bone", "PSA Progression", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 14, "start_date": "2016-01-26", "completion_date": "2021-09-14", "has_results": true, "last_update_posted_date": "2022-11-17", "last_synced_at": "2026-07-23T04:09:53.285Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02598895" }, { "nct_id": "NCT01945775", "title": "A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "BRCA 1 Gene Mutation", "BRCA 2 Gene Mutation" ], "interventions": [ { "name": "talazoparib", "type": "DRUG" }, { "name": "Physician's-Choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 431, "start_date": "2013-10-14", "completion_date": "2021-03-05", "has_results": true, "last_update_posted_date": "2022-01-20", "last_synced_at": "2026-07-23T04:09:53.285Z", "location_count": 207, "location_summary": "Flagstaff, Arizona • Scottsdale, Arizona • Antioch, California + 136 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Antioch", "state": "California" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01945775" }, { "nct_id": "NCT01506609", "title": "Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 294, "start_date": "2012-01-23", "completion_date": "2020-09-02", "has_results": true, "last_update_posted_date": "2021-10-25", "last_synced_at": "2026-07-23T04:09:53.285Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01506609" }, { "nct_id": "NCT00165152", "title": "Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "Genetic Counseling", "type": "PROCEDURE" }, { "name": "Informed Consent Counseling", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 150, "start_date": "1998-07", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2012-08-09", "last_synced_at": "2026-07-23T04:09:53.285Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00165152" }, { "nct_id": "NCT02034916", "title": "A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "BRCA 1 Gene Mutation", "BRCA 2 Gene Mutation" ], "interventions": [ { "name": "talazoparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2013-12-13", "completion_date": "2018-10-31", "has_results": true, "last_update_posted_date": "2019-10-14", "last_synced_at": "2026-07-23T04:09:53.285Z", "location_count": 37, "location_summary": "Greenbrae, California • Los Angeles, California • Palo Alto, California + 19 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02034916" }, { "nct_id": "NCT05787587", "title": "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Breast Cancer", "Ovarian Cancer", "Prostate Cancer", "Endometrial Cancer", "Colorectal Cancer", "Head and Neck Cancers", "Extensive Stage Small Cell Lung Cancer (ES-SCLC)", "NSCLC" ], "interventions": [ { "name": "IDE-161", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IDEAYA Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 216, "start_date": "2023-04-18", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-07-23T04:09:53.285Z", "location_count": 27, "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05787587" }, { "nct_id": "NCT02154633", "title": "Lessons Learned From the Family Gene Toolkit", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Women With BRCA 1 or BRCA 2 Mutation", "Non-tested Female Family Members" ], "interventions": [ { "name": "Family Gene Toolkit", "type": "BEHAVIORAL" }, { "name": "Delayed Family Gene Toolkit", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 13, "start_date": "2010-09-30", "completion_date": "2017-03-31", "has_results": false, "last_update_posted_date": "2020-02-25", "last_synced_at": "2026-07-23T04:09:53.285Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02154633" }, { "nct_id": "NCT02000622", "title": "Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer Metastatic", "BRCA 1 Gene Mutation", "BRCA 2 Gene Mutation" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Physician's choice chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 302, "start_date": "2014-03-27", "completion_date": "2025-12-23", "has_results": true, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-07-23T04:09:53.285Z", "location_count": 42, "location_summary": "San Diego, California • Santa Rosa, California • Whittier, California + 35 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02000622" }, { "nct_id": "NCT03805919", "title": "Men at High Genetic Risk for Prostate Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostatic Neoplasms" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "75 Years", "sex": "MALE", "summary": "30 Years to 75 Years · Male only" }, "enrollment_count": 500, "start_date": "2019-03-27", "completion_date": "2039-01-01", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-07-23T04:09:53.285Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03805919" }, { "nct_id": "NCT02000089", "title": "The Cancer of the Pancreas Screening-5 CAPS5)Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreas Cancer", "Peutz-Jeghers Syndrome (PJS)", "Gene Mutation", "Germline Mutation Carrier", "Lynch Syndrome" ], "interventions": [ { "name": "Secretin", "type": "DRUG" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "Tumor marker gene test with CA19-9", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9000, "start_date": "2014-01-06", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-07-23T04:09:53.285Z", "location_count": 9, "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02000089" } ] }